Uniqure NV (NASDAQ:QURE)
| 41.63 Delayed Data As of Aug 13 |  +0.16 / +0.39%Today’s Change | 36.20 Today|||52-Week Range 76.69 | -41.91% Year-to-Date |
Latest QURE News | Press Releases
| Genomic Medicine: Summer 2020 Update Aug 13 / Seeking Alpha - Paid Partner Content | uniQure EPS misses by $0.31, misses on revenue Jul 30 / Seeking Alpha - Paid Partner Content |
| A Quick Investment Idea On uniQure Jul 30 / Seeking Alpha - Paid Partner Content |
Today’s Trading
| Previous close | 41.53 |
| Today’s open | 41.63 |
| Day’s range | 41.21 - 42.12 |
| Volume | 203,870 |
| Average volume (3 months) | 534,576 |
| Market cap | $1.8B |
Data as of 3:59pm ET, 08/13/2020
Growth & Valuation
| Earnings growth (last year) | -32.84% |
| Earnings growth (this year) | +114.35% |
| Earnings growth (next 5 years) | -26.60% |
| Revenue growth (last year) | -35.48% |
| P/E ratio | NM |
| Price/Sales | 393.68 |
| Price/Book | 5.58 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| XNCRXencor Inc | +0.84 | +2.58% |
| MCRBSeres Therapeutics I... | +5.02 | +21.31% |
| AUPHAurinia Pharmaceutic... | -0.01 | -0.07% |
| SGMOSangamo Therapeutics... | -0.06 | -0.51% |
Data as of 4:47pm ET, 08/13/2020
Financials
| Next reporting date | November 3, 2020 |
| EPS forecast (this quarter) | $2.20 |
| Annual revenue (last year) | $7.3M |
| Annual profit (last year) | -$124.2M |
| Net profit margin | -1,705.82% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Amsterdam, Noord-holland |
Forecasts
